News & Events

• March 1, 2013
  

  The advantages of frontotemporal degeneration drug development (Part 2 of frontotemporal degeneration: the next therapeutic frontier)

• March 1, 2013
  

  Global standardization measurement of cerebral spinal fluid for Alzheimer’s disease: an update from the Alzheimer’s Association Global Biomarkers Consortium

• February 21, 2013
  

  Critical Path Institute Names Martha Brumfield CEO

  The Board of Directors of the Critical Path Institute (C-Path) announced today that Martha Brumfield, Ph.D., has been named interim president and chief executive officer of the organization. Brumfield, C-Path’s former director of International & Regulatory Programs, takes over immediately for Carolyn Compton, M.D., Ph.D., who will be assuming a new position at Arizona State...
• January 31, 2013
  

  Predictive Safety Testing Consortium Activities

  Presenter – N King Conference – 38th Annual Winter Meeting of the Toxicology Forum
• January 29, 2013
  

  CFAST Announces Parkinson’s Disease Drug Development Milestone: Release and Availability of a PD Therapeutic Area Data Standard